Safety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study

Mohammad Javad  Zibaeenezhad; H  Kamfiroozi; Kamran Aghasadeghi

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Safety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study

Author(s):

Mohammad Javad Zibaeenezhad^1,*,

H Kamfiroozi¹,

Kamran Aghasadeghi¹

1Cardiovascular Research Center, Shiraz University of Medical Science, Shiraz, Iran

International Cardiovascular Research Journal:Vol. 1, issue 3; e79524

Published online:Sep 30, 2007

Article type:Research Article

Received:May 22, 2018

Accepted:Sep 30, 2007

How to Cite:Mohammad Javad ZibaeenezhadH KamfirooziKamran AghasadeghiSafety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study.Int Cardiovasc Res J.1(3):e79524.

Abstract

Background: Unfractioned heparin (UFH) is the standard antithrombotic agent in elective percutaneous coronary intervention (PCI), but has its own limitations. Several studies have suggested intravenous enoxaparin as a safe and effective alternative but most of them are uncontrolled. Our main goal was to evaluate the safety of enoxaparin over UFH in PCI patients undergoing coronary stenting by drug eluting stents (DES).
Methods: We randomly assigned 195 patients undergoing PCI using DES to receive either 0.75 mg enoxaparin per kilogram of body weight or 10000 IU unfractioned heparin. The primary end point was the incidence of major or minor bleeding . The secondary end point was the incidence of acute coronary events (ST-elevation myocardial infarction, non ST-elevation myocardial infarction,and unstable angina) in the first 24 hours after PCI.
Results: The rate of major and minor bleedings was similar in the first 24 hours after procedure between enoxaparin group and UFH group ( P value>0.05). The incidence of acute coronary events and mortality was also similar between two arms.
Conclusion: In DES based PCI , a single intravenous bolus of 0.75 mg of enoxaparin per kilogram is associated with similar rate of bleeding as compaired with UFH. Also the rates of ischemic events are not different for enoxaparin and UFH however larger trials are needed for definit conclusion.

Keywords

Enoxaparin

PCI

DES

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments